Nexesta Fe Kit
Product Images NDC 65862-926

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Nexesta Fe (NDC 65862-926). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Norethindroneethinyl Fig1)

A forest plot chart showing effect estimates with odds ratios or relative risks (OR/RR) for various women's health studies from 2002 to 2017. The horizontal axis represents the effect estimate scale, ranging approximately from -1.5 to 2, with individual study data points and confidence intervals plotted to the right of a vertical line at 1.0.*

FDA Label Image

Figure A (Norethindroneethinyl Fig2)

A vertical arrow chart showing pregnancy rates per 100 women per year. Along the arrow from fewer to more pregnancies, birth control methods are listed by effectiveness: implants, injections, intrauterine devices, and sterilization (fewer pregnancies); birth control pills, skin patch, vaginal ring with hormones; condoms and diaphragm; no sex during fertile days, spermicide, withdrawal; and no birth control (more pregnancies).*

FDA Label Image

Figure3 (Norethindroneethinyl Fig3)

An instructional diagram for Nexesta Fe chewable tablets kit (norethindrone and ethinyl estradiol 0.4 mg/0.035 mg with ferrous fumarate). It shows a 28-day tablet calendar divided by week and day, indicating Weeks 1, 2, 3 as active tablets and Week 4 as inactive tablets, with Sunday through Saturday columns for daily tablet intake.*

FDA Label Image

Package Label-principal Display Panel (0.4 mg/0.035 mg Pouch Label)

An instructional line drawing showing two hands using their fingers to press and release a tablet from a blister pack. Two large arrows point downward toward the fingers applying pressure, indicating how to push a pill out of the packaging. The illustration demonstrates the proper method to remove tablets from a blister strip.*

FDA Label Image

Package Label-principal Display Panel (0.4 mg/0.035 mg Blister Carton)

Label for Nexesta Fe kit by Aurobindo Pharma Limited, containing chewable tablets with norethindrone 0.4 mg, ethinyl estradiol 0.035 mg, and ferrous fumarate. The label details tablet colors and counts: 21 white to off-white tablets with hormones and 7 brown tablets with ferrous fumarate. It includes dosage information, storage instructions, and a note that it is Rx only with one blister of 28 tablets.*

FDA Label Image

Norethindroneethinyl Fig6

Nexesta Fe kit packaging label containing norethindrone and ethinyl estradiol tablets USP (chewable) 0.4 mg/0.035 mg and ferrous fumarate tablets (chewable). The label includes dosage information, storage instructions, warnings, and contact information for adverse reaction reporting. Distributed by Aurobindo Pharma USA, Inc., the label features product branding and a barcode, indicating the kit contains 5 pouches of 28 tablets each.*

FDA Label Image

Chemical Structure (Norethindroneethinyl Str1)

Chemical structure diagrams of norethindrone and ethinyl estradiol, the active ingredients in the Nexesta Fe prescription drug kit by Aurobindo Pharma Limited. The image shows the molecular layouts including functional groups and bonds for both steroid-based compounds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.